Summary
70% of medicines given to children have never been studied in pediatric populations. Children who need treatments represent a relatively small population. This alone presents unique challenges for pediatric drug development. Since the 1990s, authorities around the world have worked to solve these issues, enacting legislations to encourage pediatric drug development plans—but there is still more to do. This two-part paper discusses the role global collaboration will play in bringing life-changing drugs to children who need them most. Download to read Part Two or click here to read Part One.
Register to download
Global Pediatric Drug Development Collaboration Part Two
You may also be interested in:
page
The RACE Act
Our team is here to help you prepare for this historic transition in our industry. We’ll be updating this page bi-weekly with need-to-know RACE Act…
White Paper
Global Pediatric Drug Development Collaboration Part One
The pharmaceutical industry is unlike any other industry in that the products manufactured can dramatically improve, and even save, lives. This is…
White Paper
Parents as Gatekeepers for Children with Cancer
The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular…